1017O NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma
| Autor: | Borgers, J.S.W., Lenkala, D., McCarthy, B., Kohler, V., Hymson, S., Esaulova, K., Finney, O., Balogh, K., Klobuch, S., Nijenhuis, C., Gaynor, R.B., DeMario, M., Haanen, J.B.A.G., van Buuren, M.M. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S619-S619 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|